Search Results - "Zemzemi, N."

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Comparison of two segmentation software tools for deep brain stimulation of the subthalamic and ventro-intermedius nuclei by Constanthin, P. E., Zemzemi, N., Cuny, E., Engelhardt, J.

    Published in Acta neurochirurgica (01-11-2023)
    “…Purpose Deep brain stimulation (DBS) relies on precise targeting of key structures such as the subthalamic nucleus (STN) for Parkinson’s disease (PD) and the…”
    Get full text
    Journal Article
  2. 2

    Effects of L-type calcium channel and human ether-a-go-go related gene blockers on the electrical activity of the human heart: a simulation study by Zemzemi, Nejib, Rodriguez, Blanca

    Published in Europace (London, England) (01-02-2015)
    “…Class III and IV drugs affect cardiac human ether-a-go-go related gene (IKr) and L-type calcium (ICaL) channels, resulting in complex alterations in…”
    Get full text
    Journal Article
  3. 3

    A Coupled System of PDEs and ODEs Arising in Electrocardiograms Modeling by Boulakia, M., Fernandez, M. A., Gerbeau, J.-F., Zemzemi, N.

    Published in Applied mathematics research express (01-01-2008)
    “…We study the well-posedness of a coupled system of PDEs and ODEs arising in the numerical simulation of electrocardiograms. It consists of a system of…”
    Get full text
    Journal Article
  4. 4

    From body surface potential to activation maps on the atria: A machine learning technique by Zemzemi, N., Labarthe, S., Dubois, R., Coudiere, Y.

    Published in 2012 Computing in Cardiology (01-09-2012)
    “…The treatment of atrial fibrillation has greatly changed in the past decade. Ablation therapy, in particular pulmonary vein ablation, has quickly evolved…”
    Get full text
    Conference Proceeding
  5. 5

    Role of L-type calcium in modulating pro-arrhythmic effects of dofetilide in humans by Zemzemi, N., Rodriguez, J. S., Rodriguez, B.

    Published in 2012 Computing in Cardiology (01-09-2012)
    “…Dofetilide is a class III drug whose use needs to be monitored due to the possible occurrence of Torsades de Pointes (TdP). The mechanisms are unclear but…”
    Get full text
    Conference Proceeding